A cost-effectiveness analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors based on their lowering of low-density lipoprotein cholesterol (LDL-C) demonstrated that the 2015 price of PCSK9 inhibitors would need to be reduced by more than two-thirds (to $4536 per year) to meet generally accepted cost-effectiveness thresholds.
Methods | As with the prior analysis, 1 the Cardiovascular Disease Policy Model (CVDPM) was used to estimate the costeffectiveness of PCSK9 inhibitors or ezetimibe added to statin therapy among US adults with atherosclerotic cardiovascular disease (ASCVD) from a health system perspective and a lifetime analytic horizon. The primary outcome was the Editorial page 711 c To approximate the study population of the FOURIER trial. Baseline characteristics derived from NHANES based on inclusion criteria, age, and sex. d Consistent with the LDL hypothesis, the base case assumed a constant relative reduction in the risk of coronary heart disease and stroke for each millimole per liter reduction in LDL-C, independent of the agent or agents used to lower LDL-C (statin, statin + ezetimibe, or statin + PCSK9 inhibitor). RR for coronary heart disease per 1-mmol/L reduction in LDL-C was 0.76; RR for stroke per 1-mmol/L reduction in LDL-C was 0.85. e The updated analysis models the effectiveness of PCSK9 inhibitors based on event rates observed in the FOURIER trial. Different risk ratios were used for the first and subsequent years to reflect the increasing effectiveness of PCSK9 inhibitors seen in FOURIER. RR for coronary heart disease for statin + PCSK9 inhibitors relative to statins alone was 0.80 for year 1, and 0.65 for years 2 or more. RR for stroke for statin + PCSK9 inhibitors relative to statins alone was 0.83 for year 1, and 0.76 for years 2 or more. The effectiveness of statin alone and that of statin + ezetimibe were unchanged from the prior analysis. Reductions in myocardial infarction and stroke risk were estimated from FOURIER, with separate hazard ratios for the first year and subsequent years to account for the increasing effectiveness over time observed in the trial ( ; all other health care costs were inflated to 2017 US dollars. Because PCSK9 inhibitors did not reduce risk of cardiovascular death in FOURIER, we conducted an additional analysis with no effect on cardiovascular death except as a direct result of lowering myocardial infarction or stroke risk. Table 1 compares the approach in the prior analysis and this update.
The CVDPM is programmed in Fortran 95 (Lahey Computer Systems). Outcomes were analyzed using QuickBasic 64 and Excel 2011 (Microsoft); statistical analyses were performed using SAS (SAS Institute), version 9.4, and Stata (StataCorp), version 13.
Results | Approximately 8.9 million US adults meet the age, ASCVD, LDL-C, and statin treatment criteria of FOURIER. Based on NHANES, this population is 61% men (95% CI, 55%-67%), with a mean age of 66 years (95% CI, 65-68), mean LDL-C of 104 mg/dL (95% CI, 100-108), and diabetes proportion of 33% (95% CI, 28%-39%). The CVDPM accurately reproduced FOURIER MACE rates (statin only: FOURIER estimate, 3.7% in year 1, 3.7% in year 2; CVDPM, 3.6% in year 1, 3.8% in year 2; statin plus PCSK9 inhibitors: FOURIER estimate, 3.1% in year 1, 2.7% in year 2; CVDPM, 3.0% in year 1, 2.7% in year 2). Adding PCSK9 inhibitors to statins was estimated to prevent 2 893 500 more MACE compared with adding ezetimibe, at an ICER of $450 000/QALY (80% uncertainty interval, $301 000-$787 000) ( Table 2) . Reducing annual drug costs by 71% (to ≤$4215) would be needed for PCSK9 inhibitors to be costeffective at a threshold of $100 000/QALY. Assuming no direct effect on cardiovascular death as observed in FOURIER, the ICER increased to $1 795 000/QALY. Discussion | PCSK9 inhibitor use in patients with ASVCD was not cost-effective at 2017 prices, and these updated analyses based on FOURIER estimates suggest that even greater price reductions than previously reported are required to meet cost-effectiveness thresholds. The 71% price reduction required to make PCSK9 inhibitor therapy cost-effective is greater than the 25% to 30% discounts typically offered by manufacturers. 5 Abbreviations: ASCVD, atherosclerotic cardiovascular disease; MACE, major adverse cardiovascular events; NNT, number needed to treat; PCSK9, proprotein convertase subtilisin/kexin type 9; QALY, quality-adjusted life-year. a The model assumed the health system perspective and a lifetime analytic horizon, and discounted future costs and QALYs at 3% a year. To reflect the precision of the model, MACE and QALYs are rounded to the 100s; costs are rounded to the millions; and incremental cost-effectiveness ratios to the 1000s. This analysis included patients with a history of ASCVD and low-density lipoprotein cholesterol of 70 mg/dL or more taking statin therapy (n = 8 947 000 in 2015). b MACE was defined as a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular causes.
c No. of patients that would need to be treated for 5 years to avert 1 MACE.
d This is the number of patients that would have to be treated for 5 years with statin + PCSK9 inhibitor compared with statin + ezetimibe to avoid 1 MACE. For context, 20 patients would have to be treated for 5 years with statin + PCSK9 inhibitor compared with statin alone to avoid 1 MACE. e All costs are reported in 2017 US dollars.
f Noncardiovascular costs include age-specific background health care costs (ie, health care costs unrelated to management of cardiovascular disease). g For reference purposes, the incremental cost-effectiveness ratio of the statins + PCSK9 inhibitor group relative to statin therapy was $339 000/QALY (80% uncertainty interval, $284 000 to $430 000). 2) in inpatient, outpatient, and professional claims. We included patients with 6 months of continuous enrollment in Medicaid before and after the overdose claim (limiting our analyses to nonfatal opioid overdoses). We measured all nonparenteral prescription opioid use in pharmacy claims. We used Current Procedural Terminology codes (H0020, J1230) in professional claims to capture methadone dispensed for OUD in an opioid treatment program (as opposed to prescriptions for pain management). We used National Drug Codes in pharmacy claims to identify OUD-approved buprenorphine and naltrexone. We used a logistic regression model with generalized estimating equations for correlated data to estimate differences from before to after overdose in prescription opioid use (any use and receipt of ≥90 cumulative days duration) and differences in receiving MAT (overall and each medication separately). Analyses were stratified by overdose type (prescription opioid vs heroin) and conducted using SAS (SAS Institute), version 9.4, and STATA (StataCorp), version 14. We considered 2-sided
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